** Shares of telehealth firm Hims & Hers HIMS.N rise 11.2% to $32.88
** HIMS says it plans to sell Eli Lilly's LLY.N weight-loss and diabetes drug on its platform
** Co says it will offer both branded versions of Lilly's tirzepatide, the active ingredient in weight loss drug Zepbound and diabetes medicine Mounjaro, as well as generics of Novo Nordisk's NOVOb.CO diabetes drug, liraglutide
** HIMS joins its peers such as Teladoc TDOC.N and LifeMD LFMD.O to offer Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs
** Including session's moves, HIMS stock up 36.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。